MX2025005174A - Formulacion oral de derivado de n-piridinilacetamida para tratar la enfermedad pulmonar intersticial - Google Patents
Formulacion oral de derivado de n-piridinilacetamida para tratar la enfermedad pulmonar intersticialInfo
- Publication number
- MX2025005174A MX2025005174A MX2025005174A MX2025005174A MX2025005174A MX 2025005174 A MX2025005174 A MX 2025005174A MX 2025005174 A MX2025005174 A MX 2025005174A MX 2025005174 A MX2025005174 A MX 2025005174A MX 2025005174 A MX2025005174 A MX 2025005174A
- Authority
- MX
- Mexico
- Prior art keywords
- interstitial lung
- lung disease
- oral formulation
- acetamide derivative
- treating interstitial
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción se relaciona con formulaciones orales de un derivado de n piridinilacetamida, y al uso de tales formulaciones en el tratamiento de enfermedades pulmonares intersticiales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263382311P | 2022-11-04 | 2022-11-04 | |
| PCT/EP2023/080652 WO2024094844A1 (en) | 2022-11-04 | 2023-11-03 | Oral formulation of n-pyridinyl acetamide derivative for treating interstitial lung disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025005174A true MX2025005174A (es) | 2025-06-02 |
Family
ID=88689993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025005174A MX2025005174A (es) | 2022-11-04 | 2025-05-02 | Formulacion oral de derivado de n-piridinilacetamida para tratar la enfermedad pulmonar intersticial |
Country Status (14)
| Country | Link |
|---|---|
| JP (1) | JP2025536575A (es) |
| KR (1) | KR20250099240A (es) |
| CN (1) | CN120187430A (es) |
| AR (1) | AR130952A1 (es) |
| AU (1) | AU2023374727A1 (es) |
| CL (1) | CL2025001306A1 (es) |
| CO (1) | CO2025007400A2 (es) |
| CR (1) | CR20250229A (es) |
| DO (1) | DOP2025000103A (es) |
| IL (1) | IL320576A (es) |
| MX (1) | MX2025005174A (es) |
| PE (1) | PE20251575A1 (es) |
| TW (1) | TW202434248A (es) |
| WO (1) | WO2024094844A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017007218B1 (pt) | 2014-10-08 | 2023-10-10 | Redx Pharma Plc | Derivados de n-piridil acetamida como inibidores da via de sinalização de wnt, formulações farmacêuticas compreendendo os mesmos e seus usos |
-
2023
- 2023-11-03 CN CN202380078161.XA patent/CN120187430A/zh active Pending
- 2023-11-03 WO PCT/EP2023/080652 patent/WO2024094844A1/en not_active Ceased
- 2023-11-03 TW TW112142363A patent/TW202434248A/zh unknown
- 2023-11-03 AU AU2023374727A patent/AU2023374727A1/en active Pending
- 2023-11-03 CR CR20250229A patent/CR20250229A/es unknown
- 2023-11-03 JP JP2025524809A patent/JP2025536575A/ja active Pending
- 2023-11-03 PE PE2025000928A patent/PE20251575A1/es unknown
- 2023-11-03 KR KR1020257018380A patent/KR20250099240A/ko active Pending
- 2023-11-03 AR ARP230102947A patent/AR130952A1/es unknown
-
2025
- 2025-04-29 IL IL320576A patent/IL320576A/en unknown
- 2025-05-02 DO DO2025000103A patent/DOP2025000103A/es unknown
- 2025-05-02 CL CL2025001306A patent/CL2025001306A1/es unknown
- 2025-05-02 MX MX2025005174A patent/MX2025005174A/es unknown
- 2025-06-03 CO CONC2025/0007400A patent/CO2025007400A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202434248A (zh) | 2024-09-01 |
| CR20250229A (es) | 2025-07-11 |
| DOP2025000103A (es) | 2025-06-15 |
| CL2025001306A1 (es) | 2025-08-01 |
| WO2024094844A1 (en) | 2024-05-10 |
| KR20250099240A (ko) | 2025-07-01 |
| PE20251575A1 (es) | 2025-06-12 |
| CN120187430A (zh) | 2025-06-20 |
| AR130952A1 (es) | 2025-02-05 |
| JP2025536575A (ja) | 2025-11-07 |
| CO2025007400A2 (es) | 2025-06-16 |
| AU2023374727A1 (en) | 2025-06-19 |
| IL320576A (en) | 2025-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| MX2020010603A (es) | Extracto de cáñamo para tratamiento de dolor en animales. | |
| EP4338804A3 (en) | Epinephrine spray formulations | |
| NO20060307L (no) | Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet | |
| MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
| BRPI0418157A (pt) | terapêutica de tumores alogênicos | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| JOP20220259A1 (ar) | تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها | |
| WO2023043870A8 (en) | Chewing gum formulation of lsd and methods of use thereof | |
| AU2001266289A1 (en) | 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury | |
| NO20071238L (no) | Fremgangsmater for leging av skader ved human IL-18 administrering | |
| MX2025005597A (es) | Compuestos antisenescencia novedosos y composiciones de los mismos | |
| CA3155674A1 (en) | Pimobendan formulation and method of use thereof | |
| WO2022043273A3 (en) | Oral care composition comprising a fructanase | |
| MX2023010918A (es) | Metodos y composiciones para el tratamiento de enfermedades oculares. | |
| NO20055390L (no) | Thorium-227 for anvendelse i radioterapi pa mykvevssykdommer | |
| MX2022014888A (es) | Propanodioles mononitrosilados y bisnitrosilados para su uso terapéutico. | |
| MX2024014811A (es) | Composiciones de menaquinol pegilado y metodos de tratamiento | |
| BRPI0412408A (pt) | métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste | |
| MX2008002456A (es) | Uso de ambroxol para el tratamiento de infecciones por rinovirus. | |
| EA202190798A1 (ru) | Ротамерные изомеры 4-алкил-5-гетероарил-3h-1,2-дитиол-3-тионов |